Developing cost effective, efficacious and safe sub-unit vaccines based on a patented highly immunogenic virus-like-particle platform, VLP Biotech, Inc. is a biotechnology company working on novel vaccines and therapies for prophylaxis and the treatment of infectious diseases and other disorders. Using the firm's patented virus-like particle platform - eliciting highly targeted antibody and cellular responses - the company's development platform (VLP) is employed to find vaccines and treatments for chronic carriers of HBV (Hepatitis B-causing virus), malaria, and respiratory syncytical virus. The firm's efforts are protected by composition and methods patents held by the Vaccine Research Institute of San Diego and exclusively licensed to VLP Biotech, Inc. Additionally, VLP Biotech employs several proprietary technologies necessary to the efficient construction, screening and optimization of new VLP vaccine candidates.
